New England Journal of Medicine· 2012Q1· Clinical trial

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

Srđan Verstovšek, Ruben A. Mesa, Jason Gotlib, Richard S. Levy et al.

2,069citations
Q1SCImago
2012year

Short summary

Ruxolitinib significantly reduced spleen size by at least 35% in 41.9% of myelofibrosis patients compared to 0.7% on placebo, and improved overall survival.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Genetics

GeneticsMedicine